Enovis Corporation $ENOV Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Enovis Corporation (NYSE:ENOV) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 712,810 shares of the company’s stock after acquiring an additional 67,021 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.25% of Enovis worth $27,236,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its position in shares of Enovis by 266.7% during the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company’s stock worth $27,000 after buying an additional 536 shares in the last quarter. Quarry LP grew its position in shares of Enovis by 506.1% during the fourth quarter. Quarry LP now owns 897 shares of the company’s stock worth $39,000 after buying an additional 749 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Enovis by 144.8% during the first quarter. GAMMA Investing LLC now owns 1,170 shares of the company’s stock worth $45,000 after buying an additional 692 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in shares of Enovis by 57.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 1,981 shares of the company’s stock worth $74,000 after buying an additional 725 shares in the last quarter. Finally, McIlrath & Eck LLC acquired a new stake in shares of Enovis during the fourth quarter worth approximately $152,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analysts Set New Price Targets

ENOV has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price target on shares of Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. JMP Securities reduced their price objective on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. UBS Group reduced their price objective on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Needham & Company LLC reduced their price objective on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group reduced their price objective on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $51.00.

Insider Transactions at Enovis

In other news, CFO Phillip Benjamin (Ben) Berry bought 2,500 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average cost of $29.71 per share, with a total value of $74,275.00. Following the completion of the acquisition, the chief financial officer directly owned 116,729 shares in the company, valued at approximately $3,468,018.59. The trade was a 2.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.70% of the stock is currently owned by insiders.

Enovis Price Performance

Shares of NYSE ENOV opened at $29.9940 on Thursday. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.83. The firm’s 50-day simple moving average is $30.13 and its 200 day simple moving average is $34.31. The company has a quick ratio of 1.15, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The stock has a market cap of $1.71 billion, a P/E ratio of -2.10 and a beta of 1.70.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The business had revenue of $564.50 million for the quarter, compared to analysts’ expectations of $555.80 million. During the same period in the previous year, the business earned $0.62 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Equities analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.